The return on investment is low, and many large pharmaceutical companies have abandoned the field. According to the authors, ...

A new Lancet study forecast what may happen over the next 25 years if more isn't done to address antimicrobial resistant ...

The return on investment is low, and many large pharmaceutical companies have abandoned the field. According to the authors, collaboration and risk-sharing can help keep companies in anti-infective ...

Sulopenem etzadroxil is an investigational oral penem anti-infective that has been combined with probenecid in a bilayer tablet. The resubmission includes additional data from the phase 3 REASSURE ...

Antibiotic resistance is a global public health threat. Modern health systems rely on antibiotics to prevent and treat ...

Farm Animal Drug Market reaching a valuation of USD 33,211.3 million by 2034 at a Compound Annual Growth Rate (CAGR) of 5.5%.

Fosmanogepix is a first-in-class antifungal treatment candidate with a novel mechanism of action. It is available in intravenous and oral formulations and has been evaluated for efficacy and safety in ...

Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority ...

Basilea Pharmaceutica (SIX: BSLN) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of ...

A new nationwide Danish study published in The Lancet Psychiatry found that individuals with schizophrenia spectrum disorders ...

MANILA, Philippines — The Department of Health (DOH) has expressed alarm over the shortage of anti-tuberculosis drugs, saying the existing supply will not cover over 365,000 TB patients targeted ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...